Smartkarma Newswire

Cboe Global Markets, Inc. (CBOE)

202.24 USD +4.99 (+2.53%) Volume: 2.32M

With a strong performance in the stock market, Cboe Global Markets, Inc.’s stock price hit 202.24 USD, reflecting a positive trading session with a +2.53% increase. The trading volume stood at 2.32M, underlining the heightened interest among investors. Impressive gains are also seen in the year-to-date (YTD) performance, with a percentage change of +13.26%, showcasing the financial robustness of CBOE.

Latest developments on Cboe Global Markets, Inc.

Cboe Global Markets has been making headlines recently with a series of key announcements and developments. The company reported trading volume for July 2024, showcasing a strong performance in the market. Despite this, the stock price has been rising but still underperforming the overall market. Cboe also announced the planned launch of options on VIX futures, expanding their volatility product suite. With an upgrade in relative strength rating and a focus on importing global trading into the US, Cboe is positioning itself for growth. Additionally, insider sales by EVP Dave Howson and the purchase of the former headquarters in the Loop indicate strategic moves within the company. Investors are bracing for a ‘regime shift’ as market volatility returns, with Cboe expected to benefit from this trend. Analysts have given Cboe new price targets, with Barclays boosting it to $218.00, highlighting the potential for further growth in the stock price.

A look at Cboe Global Markets, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

The long-term outlook for Cboe Global Markets, as indicated by the Smartkarma Smart Scores, shows a promising future for the company. With a strong score in Growth and Momentum, Cboe Global Markets is positioned well for expansion and continued success in the market. This indicates that the company is likely to see continued growth in its operations and market presence over time.

Although Cboe Global Markets has average scores in Value and Dividend, its high scores in Growth and Momentum suggest that it has the potential to outperform in the long run. Additionally, with a Resilience score of 3, the company shows a moderate level of stability and ability to withstand market fluctuations. Overall, Cboe Global Markets appears to have a positive outlook for its future performance and growth in the trading of standardized options on equity securities.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Henry Schein, Inc. (HSIC)

65.77 USD +1.85 (+2.89%) Volume: 3.49M

Henry Schein, Inc.’s stock price is currently at 65.77 USD, witnessing a promising surge of +2.89% this trading session with a trading volume of 3.49M, despite a year-to-date percentage change of -13.13%, indicating a potential turn-around for HSIC stock performance.

Latest developments on Henry Schein, Inc.

Henry Schein, Inc. has been facing challenges following a cyber incident, impacting its Q2 results and leading to a slow recovery. The company recently announced layoffs as part of a plan to save $75M to $100M amidst underperformance compared to competitors. Despite beating estimates in Q2 earnings, Henry Schein has cut its annual profit forecast due to the lingering impact of the cyberattack. This has led to a decline in stock price and a revision of the 2024 financial guidance, warning of a slower recovery. The company’s Q2 earnings call highlighted these issues, reflecting a mixed performance and a need for cautious optimism moving forward.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Enphase Energy, Inc. (ENPH)

103.42 USD +1.89 (+1.86%) Volume: 3.29M

Enphase Energy, Inc.’s stock price is currently at 103.42 USD, marking a positive shift of +1.86% in this trading session. Despite the trading volume of 3.29M, the stock has experienced a year-to-date decrease of -21.73%, indicating a volatile year for ENPH.

Latest developments on Enphase Energy, Inc.

Enphase Energy (NASDAQ:ENPH) has been making waves in the stock market recently with key events driving its stock price movements. BNP Paribas upgraded Enphase Energy to “Outperform”, highlighting positive growth potential. The company also launched IQ8 Microinverters for high-powered solar panels in the Caribbean, expanding its market reach. Despite a 20.4% YTD plunge, analysts see this as a buying opportunity, signaling better times ahead for Enphase Energy.

Enphase Energy, Inc. on Smartkarma

Analysts on Smartkarma, like Baptista Research and Joe Jasper, have been closely following Enphase Energy‘s financial performance and growth prospects. Baptista Research highlighted Enphase Energy‘s solid financial outcomes for the second quarter of 2024, driven by robust demand for its products and effective inventory management. The company reported a revenue of $303.5 million, reflecting strong shipments of microinverters and batteries, supported by an overall end market demand valued at around $396 million for the quarter.

In another report, Baptista Research discussed Enphase Energy‘s first quarter 2024 financial results, where the company reported a total revenue of $263.3 million, a slight decrease compared to the previous quarter. Despite this, Enphase Energy managed to ship a significant number of microinverters and batteries, leading to a free cash flow of $41.8 million. Analysts are optimistic about Enphase Energy‘s growth potential, with a focus on its solar-plus-storage products as a critical growth catalyst for the company’s future performance.

A look at Enphase Energy, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Enphase Energy, a company that manufactures solar power solutions, has a mixed outlook based on the Smartkarma Smart Scores. While it scores high in resilience and growth, indicating its ability to withstand challenges and potential for expansion, its value and dividend scores are lower. This suggests that the company may not be considered a strong investment for those seeking immediate returns or income through dividends.

Looking ahead, Enphase Energy‘s momentum score also falls in the middle range, showing that the company is neither strongly trending upwards nor downwards. Overall, the company’s focus on increasing productivity and reliability of solar modules positions it well for long-term growth and sustainability in the renewable energy sector, despite some areas of weakness in its financial outlook.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Super Micro Computer, Inc. (SMCI)

492.70 USD -124.24 (-20.14%) Volume: 17.99M

Super Micro Computer, Inc.’s stock price currently stands at 492.70 USD, experiencing a sharp drop of -20.14% this trading session, with a trading volume of 17.99M. Despite the recent fall, SMCI’s stock still boasts a positive YTD change of +73.33%, reflecting its robust performance over the year.

Latest developments on Super Micro Computer, Inc.

Super Micro Computer stock took a hit today after the company announced a 10-for-1 stock split, causing shares to plunge. The stock price movements were also influenced by concerns over Nvidia delays and AI demand, leading to a crash of 16%. Despite the earnings results causing the stock to plummet, there is optimism that sales could double this fiscal year. Analysts have lowered price targets for Super Micro Computer, but some see it as a bargain worth buying. The company’s revenue forecast was strong, but worries over margins continue to weigh on investor sentiment. With Super Micro Computer CEO attributing underperformance to Nvidia delays, the stock price has plummeted by 20%.

Super Micro Computer, Inc. on Smartkarma

Super Micro Computer has been receiving positive analyst coverage on Smartkarma, an independent investment research network. Uttkarsh Kohli‘s report titled “Super Micro Ascends, Walgreens Exits Nasdaq-100 on 22/Jul. How Will Index Rebalancing Pan Out?” suggests that Super Micro Computer (SMCI) is set to outperform as it replaces Walgreens (WBA) in the NASDAQ index. With a 214% YTD surge and strategic partnerships with Nvidia and AMD, SMCI is poised for success while WBA has declined 56% YTD and has been excluded from the index due to falling market cap. Historically, stocks added to indices tend to outperform briefly post-announcement, and SMCI’s strong trend is driven by idiosyncratic factors.

Baptista Research also provides bullish coverage on Super Micro Computer in their report “Super Micro Computer Inc.: Role of AI and Green Computing in Market Leadership! – Major Drivers”. Highlighting the company’s strong financial performance in Q3 2024 with record-breaking revenues of $3.85 billion and non-GAAP earnings per share of $6.65, the report emphasizes Super Micro’s potential for AI growth over the coming quarters. The demand for their rack-scale plug and play total AI solutions reflects positive market trends, positioning the company for continued success in the AI and green computing sector.

A look at Super Micro Computer, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Super Micro Computer, Inc. has a positive long-term outlook based on the Smartkarma Smart Scores. With a high score in Growth and Resilience, the company is positioned for strong expansion and adaptability in the market. This indicates that Super Micro Computer is likely to experience steady growth and be able to withstand economic challenges, making it a promising investment option for the future.

Although Super Micro Computer scores lower in Value and Momentum, its high scores in Growth and Resilience outweigh these factors. The company’s focus on developing and selling server solutions based on modular and open-standard x86 architecture positions it well for continued success in the industry. Investors looking for a company with strong growth potential and resilience should consider Super Micro Computer for their portfolio.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

DexCom, Inc. (DXCM)

69.32 USD -5.93 (-7.88%) Volume: 9.99M

DexCom, Inc.’s stock price is currently at 69.32 USD, experiencing a decrease of -7.88% this trading session with a trading volume of 9.99M. Year-to-date, DXCM’s stock has seen a significant drop of -44.14%, making it a focal point for investors tracking market volatility.

Latest developments on DexCom, Inc.

Today, DexCom Inc. (NASDAQ: DXCM) investors are closely watching the stock price movements following a series of events. Kessler Topaz Meltzer & Check, LLP has issued a notice encouraging investors with significant losses to contact the firm in response to an investigation into securities fraud. Despite a traditional market overreaction to DexCom’s Q2 earnings report, the stock has outperformed competitors on a strong trading day. With shares gap down to $75.25, some investors are questioning whether DexCom stock is still a buy after a 40% drop in one day. Bragar Eagel & Squire, P.C. is also investigating the company. As investors assess the chances of DexCom Inc (DXCM) stagnating, it is important for those who suffered significant losses to explore all their legal options.

DexCom, Inc. on Smartkarma

Analysts at Baptista Research have provided bullish coverage on Dexcom Inc, a company known for its continuous glucose monitoring systems. In their research reports, they highlight the company’s strong performance in the diabetes management market, despite facing short-term challenges. Baptista Research evaluates various factors influencing the company’s stock price and conducts an independent valuation using a Discounted Cash Flow methodology.

Furthermore, Baptista Research remains optimistic about Dexcom Inc‘s future outlook, citing the company’s solid market penetration in basal and hypo non-insulin markets, as well as its international expansion efforts. The analysts note Dexcom’s significant revenue growth and the positive impact of its CGM technology, particularly with the launch of G7 in the U.S. This growth trajectory has attracted new prescribers and increased demand from individuals with diabetes, positioning Dexcom for continued success in the medical technology sector.

A look at DexCom, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Dexcom Inc has a positive long-term outlook. The company scores high in Growth, indicating strong potential for expansion and development in the future. Additionally, Dexcom scores well in Resilience, suggesting that it has the ability to withstand challenges and remain stable. However, the company’s Value and Momentum scores are lower, indicating room for improvement in these areas.

Dexcom Inc is a medical device company specializing in continuous glucose monitoring systems for individuals with diabetes. With a focus on innovation and technological advancement, Dexcom has positioned itself as a leader in the industry. The company’s high Growth and Resilience scores bode well for its future prospects, while the lower Value and Momentum scores highlight areas that Dexcom may need to address to further enhance its overall performance.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Broadcom Inc. (AVGO)

136.27 USD -7.65 (-5.32%) Volume: 29.57M

Broadcom Inc.’s stock price stands at 136.27 USD, undergoing a 5.32% decrease this trading session, with a trading volume of 29.57M. Notwithstanding the recent dip, the tech giant boasts a year-to-date growth of 22.08%, showcasing its robust market performance.

Latest developments on Broadcom Inc.

Despite losses on the day, Broadcom Inc. continues to outperform competitors, with analysts noting ‘no sign’ of AI demand slowdown for the company. With Broadcom set to announce its Third Quarter Fiscal Year 2024 financial results soon, investors are eager to see how the stock will perform. Embracing sovereignty in the cloud and riding the AI wave, Broadcom remains a top pick for many, with opportunities for growth amidst legacy declines and valuation concerns. As the market experiences a sell-off, some analysts suggest buying the dip on Broadcom stock, confident in its potential to soar above its rivals. With 25 years of Wi-Fi innovation under its belt, Broadcom remains a strong player in the tech industry, attracting investor attention for its promising future.

Broadcom Inc. on Smartkarma

Analysts on Smartkarma, including Uttkarsh Kohli and Baptista Research, are bullish on Broadcom’s growth prospects. Uttkarsh Kohli‘s report highlights Broadcom’s dominance in AI-specific circuits, strong Q2 earnings, and the potential upside from a stock split surge. Similarly, Baptista Research emphasizes Broadcom’s expansion in AI and networking technologies, citing a substantial 43% year-on-year revenue increase in the second quarter of fiscal year 2024. With a stable semiconductor and software ecosystem driving growth, Broadcom’s consolidated net revenue of $12 billion, as reported by Baptista Research, showcases the company’s robust performance in key segments.

A look at Broadcom Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Broadcom has a positive long-term outlook. With high scores in Growth and Momentum, the company is positioned well for future expansion and market performance. Additionally, with a strong Dividend score, Broadcom seems to be a reliable option for investors looking for steady income. However, the lower scores in Value and Resilience indicate potential areas of concern that investors may want to keep an eye on.

Broadcom Inc. is a company that designs, develops, and supplies semiconductor and infrastructure software solutions. They offer a range of products to modernize and secure complex hybrid environments for customers worldwide. With a strong focus on growth and momentum, Broadcom is poised to continue making advancements in the industry and providing innovative solutions to meet the needs of their customers.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Charles River Laboratories International, Inc. (CRL)

199.96 USD -28.84 (-12.60%) Volume: 3.95M

Charles River Laboratories International, Inc.’s stock price stands at 199.96 USD, witnessing a significant drop of -12.60% this trading session with a trading volume of 3.95M. The stock has experienced a downward trend YTD with a -15.41% change, reflecting its volatile performance in the market.

Latest developments on Charles River Laboratories International, Inc.

Charles River Laboratories has been facing a series of setbacks leading to a decline in its stock price today. The company recently announced that it expects sales to fall, causing its stock to tumble. Additionally, Charles River Labs cut its 2024 forecast due to lower demand for drug development services, further impacting investor confidence. Despite surpassing Q2 earnings and revenue estimates, the company’s lowered outlook has led to a negative market reaction. As a result, shares have fallen, prompting concerns among shareholders and analysts about the company’s future prospects.

A look at Charles River Laboratories International, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Charles River Laboratories International, Inc. provides research tools and support services that enable drug discovery and development. The company offers animal research models needed for the creation of new drugs, devices, and therapies. With a mixed outlook based on the Smartkarma Smart Scores, Charles River Laboratories scores well in terms of value, growth, and momentum. This indicates a positive long-term outlook for the company, suggesting potential for growth and value appreciation in the future.

However, the company’s outlook is dampened by lower scores in dividend and resilience. This suggests that Charles River Laboratories may not be as strong in terms of providing regular dividends to its investors or in weathering economic challenges. Despite these factors, the company’s strong performance in value, growth, and momentum bodes well for its future prospects in providing research tools and support services for drug discovery and development to its diverse customer base in the pharmaceutical, biotechnology, hospital, and academic sectors.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Amgen Inc. (AMGN)

312.50 USD -16.45 (-5.00%) Volume: 4.53M

Amgen Inc.’s stock price is currently at 312.50 USD, experiencing a 5.00% drop in this trading session with a trading volume of 4.53M. Despite today’s downturn, the biopharmaceutical giant’s stock maintains a positive year-to-date (YTD) increase of 8.50%, highlighting its resilience in the market and potential for growth in the biotech sector.

Latest developments on Amgen Inc.

Amgen Inc. (AMGN) reported a 45.9% decline in net income to $746 million in Q2 2024, causing its stock to fall despite beating revenue estimates and raising its full-year outlook. The company’s quarterly sales surpassed estimates, bolstered by the success of its weight-loss drug MariTide and the integration of Horizon. Analysts remain optimistic about Amgen’s long-term growth prospects, despite near-term challenges. The stock price movements today were also influenced by a patent loss to treat dialysis patients and a drug monopoly suit by a Maryland insurance provider. Overall, Amgen’s mixed Q2 results highlighted the potential of its obesity drug and upcoming clinical readouts, positioning the company for continued growth in the biopharmaceutical market.

Amgen Inc. on Smartkarma

Analysts at Baptista Research have been closely following Amgen Inc‘s recent performance and strategic moves. In their research report titled “Amgen Inc.: Will The Increased Spending on Research and Development (R&D) Pay Off? – Major Drivers,” they highlighted the company’s strong growth in Q1 of 2024, with total revenue increasing by 22% YoY. The report mentions the positive impact of strong volume growth and robust product sales from brands like Repatha, TEZSPIRE, EVENITY, Prolia, and BLINCYTO. Additionally, Amgen’s pipeline progress and development were discussed in another report by Baptista Research titled “Amgen Inc: An Analysis Of The Pipeline Progress and Development! – Major Drivers.” The analysts highlighted strategic moves, such as the acquisition of Horizon Therapeutics, and the record annual sales of 18 medicines, indicating a positive outlook for the company.

A look at Amgen Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Amgen Inc. has received a mixed outlook based on the Smartkarma Smart Scores. While the company scores high in Dividend and Momentum, indicating a strong performance in these areas, it falls short in Value and Resilience. With a moderate score in Growth, Amgen Inc. may need to focus on improving its value and resilience factors to ensure long-term success.

Despite facing some challenges in certain areas, Amgen Inc. remains a key player in the biotechnology industry. With a focus on developing innovative medicines for serious illnesses, the company’s emphasis on human therapeutics and cutting-edge research in cellular and molecular biology sets it apart in the market. By leveraging its strengths in Dividend and Momentum, Amgen Inc. can continue to make a significant impact in the healthcare sector.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma